Recs

7

Is Johnson & Johnson the Right Stock to Retire With?

Don't let it get away!

Keep track of the stocks that matter to you.

Help yourself with the Fool's FREE and easy new watchlist service today.

Now more than ever, a comfortable retirement depends on secure, stable investments. Unfortunately, the right stocks for retirement won't just fall into your lap. Let's figure out what makes a great retirement-oriented stock, then examine whether Johnson & Johnson (NYSE: JNJ  ) has what we're looking for.

The right stocks for retirees
With decades to go before you need to tap your investments, you can take greater risks, weighing the chance of big losses against the potential for mind-blowing returns. But as retirement approaches, you no longer have the luxury of waiting out a downturn.

Sure, you still want good returns, but you also need to manage your risk and protect yourself against bear markets, which can maul your finances at the worst possible time. The right stocks combine both of these elements in a single investment.

When scrutinizing a stock, retirees should look for:

  • Size. Most retirees would rather not take a flyer on unproven businesses. Bigger companies may lack their smaller counterparts' growth potential, but they do offer greater security.
  • Consistency. While many investors look for fast-growing companies, conservative investors want to see steady, consistent gains in revenue, free cash flow, and other key metrics. Slow growth won't make headlines, but it will help prevent the kind of ugly surprises that suddenly torpedo a stock's share price.
  • Stock stability. Conservative retirement investors prefer investments that move less dramatically than typical stocks, and they particularly want to avoid big losses. These investments will give up some gains during bull markets, but they won't fall as far or as fast during bear markets. Beta measures volatility, but we also want a track record of solid performance as well.
  • Valuation. No one can afford to pay too much for a stock, even if its prospects are good. Using normalized earnings multiples helps smooth out one-time effects, giving you a longer-term context.
  • Dividends. Most of all, retirees look for stocks that can provide income through dividends. Retirees want healthy payouts now and consistent dividend growth over time -- as long as it doesn't jeopardize the company's financial health.

With those factors in mind, let's take a closer look at Johnson & Johnson.

Factor

What We Want to See

Actual

Pass or Fail?

Size Market cap > $10 billion $163 billion Pass
Consistency Revenue growth > 0% in at least four of five past years 3 years Fail
  Free cash flow growth > 0% in at least four of past five years 3 years Fail
Stock stability Beta < 0.9 0.58 Pass
  Worst loss in past five years no greater than 20% (7.7%) Pass
Valuation Normalized P/E < 18 16.64 Pass
Dividends Current yield > 2% 3.6% Pass
  5-year dividend growth > 10% 10.6% Pass
  Streak of dividend increases >= 10 years 48 years Pass
  Payout ratio < 75% 43.5% Pass
       
  Total score   8 out of 10

Source: Capital IQ, a division of Standard and Poor's. Total score = number of passes.

With a score of 8, Johnson & Johnson has most of what retirees and other conservative investors want from a stock. The company has run into some growth hiccups in recent years, but that may simply give investors an opportunity to buy the stock at discounted prices.

Many see Johnson & Johnson as the all-purpose health-care stock , combining three very different yet powerful businesses. The company's consumer brands are well-known and include such names as Band-Aid, Tylenol, and Neutrogena. But consumer brands are actually J&J's smallest segment; its medical device and pharmaceutical divisions both produce considerably more revenue.

Over the past year or so, though, Johnson & Johnson has faced a seemingly never-ending string of recalls. Those recalls cost the company $900 million in lost sales last year, and more importantly, it will likely take a big campaign to lure fleeing customers back from competitors Procter & Gamble (NYSE: PG  ) and Kimberly Clark (NYSE: KMB  ) and make them comfortable with Johnson & Johnson's products again.

In addition, times have been tough in the medical-device market. Competitors Medtronic (NYSE: MDT  ) and Intuitive Surgical (Nasdaq: ISRG  ) joined J&J in reporting weak sales in the segment, with the struggling economy to blame for patients' reluctance to have elective medical procedures done. But here too, J&J's Depuy Unit recalled some of its hip replacements, potentially giving doctors second thoughts about their quality going forward.

J&J has bounced back from tough times before, though. Its recovery from its 1982 Tylenol scare is legendary, and there's no reason to believe that the company can't duplicate its success this time around. As long as the company rededicates itself to quality control, Johnson & Johnson should continue to be a good stock for retirees and others seeking dependable dividend income and stable share prices.

Keep searching
Finding exactly the right stock to retire with is a tough task, but it's not impossible. Searching for the best candidates will help improve your investing skills, and teach you how to separate the right stocks from the risky ones.

Add Johnson & Johnson to My Watchlist, which will aggregate our Foolish analysis on it and all your other stocks.

If you want to retire rich, you need to be confident that you've got the basics of your investment strategy down pat. See if you're on track by following the 13 Steps to Investing Foolishly.

Fool contributor Dan Caplinger doesn't own shares of the companies mentioned in this article. Johnson & Johnson is a Motley Fool Inside Value selection. Intuitive Surgical is a Motley Fool Rule Breakers selection. Johnson & Johnson, Kimberly Clark, and Procter & Gamble are Motley Fool Income Investor recommendations. Motley Fool Options has recommended a diagonal call position on Johnson & Johnson. The Fool owns shares of Johnson & Johnson and Medtronic. Motley Fool Alpha owns shares of Johnson & Johnson. 

We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Fool has a disclosure policy.


Read/Post Comments (0) | Recommend This Article (7)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 1456989, ~/Articles/ArticleHandler.aspx, 10/21/2014 11:28:03 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Dan Caplinger
TMFGalagan

Dan Caplinger has been a contract writer for the Motley Fool since 2006. As the Fool's Director of Investment Planning, Dan oversees much of the personal-finance and investment-planning content published daily on Fool.com. With a background as an estate-planning attorney and independent financial consultant, Dan's articles are based on more than 20 years of experience from all angles of the financial world.

Today's Market

updated Moments ago Sponsored by:
DOW 16,509.91 110.24 0.67%
S&P 500 1,927.42 23.41 1.23%
NASD 4,386.83 70.76 1.64%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/21/2014 11:12 AM
JNJ $99.65 Up +0.45 +0.45%
Johnson & Johnson CAPS Rating: ****
ISRG $488.93 Up +3.67 +0.76%
Intuitive Surgical CAPS Rating: ****
KMB $110.10 Up +2.06 +1.91%
Kimberly-Clark CAPS Rating: ****
MDT $65.03 Up +1.19 +1.87%
Medtronic CAPS Rating: *****
PG $84.53 Up +0.35 +0.42%
Procter & Gamble CAPS Rating: ****

Advertisement